We aimed to investigate 214 patients further with non-alcoholic fatty liver disease (NAFLD) as judged by transient elastography. A body mass index of ≥25 was seen in 172 (80%) of the patients. F2–F4 fibrosis, as depicted by elastography, was present in 114 (53.2%). A Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) of ≥2 was seen in 178 (83.2%). Alanine aminotransferase was elevated in 116 (54%) and aspartate aminotransferase in 88 (41.1%). Liver steatosis was significantly associated with increasing alanine aminotransferase, insulin, HOMA-IR and cholesterol levels. Regression analysis showed cholesterol as a factor independently associated with the degree of liver steatosis. The independent variable related to increasing liver elasticity was steatosis. In conclusion, a significant number of our patients with NAFLD had steatohepatitis and F2–F4 fibrosis.
ConlonBABeasleyJMAebersoldK, et al.Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients2013; 5: 4093–4114.
2.
HassanKBhallaVEl RegalME, et al.Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol2014; 20: 12082–12101.
3.
PappasGAkhtarTGergenPJ, et al.Health status of the Pakistani population: a health profile and comparison with the United States. Am J Public Health2001; 91: 93–98.
4.
ButtASHamidSJafriW, et al.Prevalence and risk factors for NAFLD among native South Asian Pakistani patients with type II diabetes and metabolic syndrome. Am J Gastroenterol2011; 1: 106–106.
5.
LoomisAKKabadiSPreissD, et al.Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. J Clin Endocrinol Metab2016; 101: 945–952.
6.
WongRJAhmedA. Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations. World J Hepatol2014; 6: 263–273.
IftikharRKamranSMSherF, et al.Prevalence of non alcoholic fatty liver disease in patients with metabolic syndrome. Pak Arm Forc Med J2015; 65: 616–619.
9.
NiazAAliZNayyarS, et al.Prevalence of NAFLD in healthy and young male individuals. ISRN Gastroenterol2011; 2011: 363546–363546.
10.
MikolasevicIOrlicLFranjicN, et al.Transientelastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease – where do we stand?World J Gastroenterol2016; 22: 7236–7251.
11.
LeeHWParkSYKimSU, et al.Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease. PLoS One2016; 11: e0157358–e0157358.
12.
CassinottoCBoursierJde LédinghenV, et al.Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology2016; 63: 1817–1827.
13.
GhasemiATohidiMDerakhshanA, et al.Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran lipid and glucose study. Acta Diabetol2015; 52: 905–915.
14.
PappachanJMBabuSKrishnanB, et al.Non-alcoholic fatty liver disease: a clinical update. J Clin Transl Hepatol2017; 5: 384–393.
15.
SanyalDMukherjeePRaychaudhuriM, et al.Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab2015; 19: 597–601.
LeiteNCSallesGFAraujoAL, et al.Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int2009; 29: 113–119.
18.
MantovaniAByrneCDBonoraE, et al.nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diab Care2018; 41: 372–382.
19.
MussoGGambinoRCassaderM, et al.Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med2011; 43: 617–649.
20.
BallestriSZonaSTargherG, et al.Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol2016; 31: 936–944.
21.
PourshamsAMalekzadehRMonavvariA, et al.Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors. J Gastroenterol Hepatol2005; 20: 229–233.
22.
Neuschwander-TetriBAClarkJMBassNM, et al.Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology2010; 52: 913–924.
23.
ChangYRyuSSungE, et al.Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem2007; 53: 686–692.
24.
AbhasneeSAkharawitPPiyapornK, et al.Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes. Asian Pac J Cancer Prev2015; 16: 1789–1794.
25.
StraussSGavishEGottliebP, et al.Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol2007; 189: W320–W323.
26.
MyersRPPollettAKirschR, et al.Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int2012; 32: 902–10.
